GET DAILY SIGNALSPolyPid Ltd. (PYPD): Following the Path of D-PLEX100 Toward Potential Commercialization
Key Takeaways
- PYPD is the Nasdaq listing for PolyPid Ltd., an Israeli clinical-stage biopharmaceutical company focused on long-acting, locally administered drug delivery.
- The company's core asset is its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, now branded Kynatrix, which enables controlled, sustained release of medicines directly at the site of care.
- Its lead product candidate, D-PLEX100, is designed to prevent surgical site infections (SSIs) after abdominal colorectal surgery and has completed a positive Phase 3 clinical trial.
- PolyPid has signed an exclusive U.S. and Canada commercialization partnership with Azurity Pharmaceuticals for D-PLEX100, while retaining rights elsewhere.
- As a pre-revenue, development-stage company, PolyPid has reported recurring losses and depends heavily on regulatory approval, financing, and partnership milestones.
Introduction
PolyPid Ltd. (PYPD) operates as a clinical-stage biopharmaceutical company based in Petah Tikva, Israel. The firm focuses on developing locally administered, long-acting controlled-release therapeutics using its own drug-delivery platform, with an emphasis on better surgical results. Its most advanced program, D-PLEX100, aims to reduce surgical site infections, which remain a notable driver of post-operative issues, longer hospital stays, and higher healthcare expenses. From what I see, investors track PolyPid due to the late-stage progress of its lead candidate, the validated nature of its delivery technology, and the steps toward possible commercialization.
Company Background and Approach
PolyPid was formed under Israeli law in 2008 and started operations on February 28 of that year. It went public on the Nasdaq Global Market via an IPO in June 2020. Leadership comes from Chief Executive Officer Dikla Czaczkes Akselbrad, who earlier held the chief financial officer role at the company. As a small-cap development-stage business, PolyPid has a workforce of roughly 60 to 75 employees and runs subsidiaries in the United States and Romania. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Central to the business model is the proprietary PLEX technology, rebranded as Kynatrix. This platform combines active pharmaceutical ingredients with a polymer-lipid encapsulation matrix to support precise, localized drug delivery at controlled rates over days to months. The aim is high local concentrations with reduced systemic exposure by targeting therapy right at the treatment site.
Lead Candidate: D-PLEX100
The company's main candidate, D-PLEX100, applies Kynatrix to deliver the broad-spectrum antibiotic doxycycline straight into the surgical site. It seeks to deliver continuous antibacterial activity for about 30 days to help prevent surgical site infections after abdominal colorectal procedures involving large incisions. The pivotal Phase 3 SHIELD II trial met its primary efficacy endpoint with a clinically meaningful drop in SSI rates compared to standard care. The FDA has awarded Breakthrough Therapy Designation, and the New Drug Application has been accepted for priority review.
Broader Pipeline and Technology Use
PolyPid is also moving forward with earlier-stage programs that apply the same delivery platform to other areas. These include oncology efforts such as OncoPLEX for solid tumors, along with work in metabolic conditions like obesity and diabetes. Early research covers a long-acting GLP-1 program and a Kynatrix-based option for diabetic foot infections. This shows how the company plans to extend one core technology across several markets, even though these remain at preclinical or early stages.
Commercialization Path
PolyPid's financial picture aligns with a typical pre-revenue biotech, funded historically through equity raises, grants, and now partnership terms. In 2026, the company entered an exclusive deal with Azurity Pharmaceuticals to commercialize D-PLEX100 in the United States and Canada. PolyPid keeps manufacturing and supply duties plus global rights outside those territories. The agreement brings upfront and milestone payments along with tiered royalties, setting up a structure for moving toward commercial operations.
Why PYPD Draws Investor Interest
Attention on PYPD centers on several longer-term elements. D-PLEX100 targets a clear unmet need, as surgical site infections are frequent and expensive complications with few localized long-acting prevention choices available. Positive Phase 3 data gives clinical support for both the candidate and the Kynatrix platform, which could open doors to other surgical and therapeutic uses. The Azurity partnership lowers some commercial risk in the key U.S. market and supplies non-dilutive funding plus milestone payments. The platform's flexibility in areas like oncology and metabolic disease adds a longer-term growth angle beyond one product.
Risks to Consider
Several notable risks warrant attention before looking at PYPD. As a clinical-stage firm, PolyPid has no approved products and has posted ongoing net losses with an accumulated deficit. Its filings have noted substantial doubt about continuing as a going concern, highlighting reliance on further financing and partnership progress. Value is heavily tied to the single lead candidate, so any regulatory delay or setback for D-PLEX100 could carry significant weight. Other factors include strong industry competition, dependence on a partner for U.S. launch, manufacturing challenges, and the usual uncertainties of FDA review. Shares in development-stage biotechs like this can show high volatility.
Using AI Tools in Research
When evaluating names like PolyPid, I find it helpful to apply structured screening tools to compare metrics across the sector. Tickeron's AI Screener serves as an AI-driven platform for identifying stocks and ETFs based on technical indicators, fundamentals, volatility, trends, AI signals, industries, patterns, and custom filters. It allows efficient review of thousands of securities to align with specific strategies, whether focused on clinical-stage biotechs or wider themes.
Conclusion
PolyPid (PYPD) is a development-stage Israeli biopharmaceutical company centered on a proprietary long-acting, locally administered drug-delivery platform. Its lead candidate, D-PLEX100, addresses a notable unmet need in surgical site infection prevention and has moved through positive late-stage data into regulatory review, backed by a U.S. commercialization partnership. While the pipeline and platform point to broader long-term potential, the pre-revenue profile and dependence on regulatory and financing outcomes mark it as a high-risk, high-uncertainty prospect that calls for careful independent review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
PYPD in upward trend: 10-day moving average broke above 50-day moving average on October 28, 2026
The 10-day moving average for PYPD crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PYPD as a result. In 109 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for PYPD just turned positive on October 22, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
PYPD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in 179 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
PYPD broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PYPD entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.147) is normal, around the industry mean (3.498). P/E Ratio (-4.687) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
Industry Biotechnology
Advertisement